CN1948507B - Parotiditis virus fluorencent amplification detection reagent box and detection method - Google Patents

Parotiditis virus fluorencent amplification detection reagent box and detection method Download PDF

Info

Publication number
CN1948507B
CN1948507B CN2006100518285A CN200610051828A CN1948507B CN 1948507 B CN1948507 B CN 1948507B CN 2006100518285 A CN2006100518285 A CN 2006100518285A CN 200610051828 A CN200610051828 A CN 200610051828A CN 1948507 B CN1948507 B CN 1948507B
Authority
CN
China
Prior art keywords
amplification
fluorencent
virus
fluorescent
parotiditis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006100518285A
Other languages
Chinese (zh)
Other versions
CN1948507A (en
Inventor
卢亦愚
严菊英
冯燕
茅海燕
徐昌平
史雯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Center for Disease Control and Prevention
Original Assignee
Zhejiang Center for Disease Control and Prevention
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Center for Disease Control and Prevention filed Critical Zhejiang Center for Disease Control and Prevention
Priority to CN2006100518285A priority Critical patent/CN1948507B/en
Publication of CN1948507A publication Critical patent/CN1948507A/en
Application granted granted Critical
Publication of CN1948507B publication Critical patent/CN1948507B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention offers detecting reagent boxes for fluorescent augment of mumps virus, which include hemagglutinin gene standards of mumps virus, detecting reagent of fluorescent augment, DNA polymerase and reverse transcriptase. The detecting reagent of fluorescent augment mainly contains buffer solution of one-step RT-PCR, specificity exciters and probes, mixture of deoxidizing triphosphoric acidand nucleoside. The partial sequence of hemagglutinin gene standards of mumps virus is 5'- CTCAAGGACTGTTTGCCTCTTACACCACAACCACCTGCTTTCAAGATACCGGTGATGCTAGTG-3'. The specificity exciters have two sequences: the sequence of upstream exciters is 5'-CTCAAGGACTRTYTGCYTCSTA-3'and the sequence of downstream exciters is 5'-CTCTRGCAT CACCGGTATCTTGAA-3'. The equence of specificity probes is 5'-FAM-ACCACAACCACCTGC-NFQ-MGB-3', in which FAM is reporting fluorescent metakliny, NFQ is non-fluorescent annihilation metakliny, MGB is modifying metakliny. The detecting reagent boxes can detect pathogen nucleic acid directly. At the early stage of mumps disease, specificity gene of mumps virus can be detected, which facilitates early isolation, diagnosis and therapy.

Description

A kind of parotiditis virus fluorencent amplification detection kit and detection method
(1) technical field
The present invention relates to a kind of parotiditis virus fluorencent amplification detection kit and detection method.
(2) background technology
Mumps is to be infected by the acute viral that mumps virus causes, this disease transmission is strong, and the four seasons all can be popular, and virus is separated and serological test is the main means of present mumps virus laboratory diagnosis.But because viral disengaging time is long, the requirement condition height, separation rate is low; The serological method susceptibility is low, is not suitable for reasons such as early diagnosis, and these two kinds of methods in use are very restricted.The regular-PCR technology is widely used in the specific detection of virogene, and it has sensitivity, special, advantage fast, needs electrophoresis but exist reaction result to judge, and reaction product is easy to generate and pollutes and cause shortcoming such as false positive.
The fluorescent quantitative PCR technique that grew up in recent years, it has utilized the efficient amplification of PCR to thymus nucleic acid (DNA), the high specific of probe technique and the susceptibility of spectroscopic techniques and quantitative characteristics, not only overcome the deficiency of conventional PCR qualitative detection, and have directly perceived, good reproducibility, high specificity, susceptibility is high and advantage such as easy to operate.
The fluorescent quantitative PCR technique principle: quantitative fluorescent PCR is to utilize the variation of the fluorescence luminous energy that fluorescence dye discharged under the effect of exciting light to come dynamically directly to reflect the variation of pcr amplification product amount.Because of the fluorescent signal variable is directly proportional with the amplified production amount, by enough sensitive automatization quantitative real time PCR Instruments just can by to the collection of fluorescent signal with analyze realize to original template quantitatively.
Fluorescence labeling method commonly used can simply be divided into two big classes: 1, non-special detection-double-stranded DNA interpolation type fluorescence dye; 2, the single-minded detection of extension increasing sequence-mainly refer to fluorescent probe and primer probe, fluorescently-labeled probe has three classes: (1) molecular beacon probe; (2) the two probes of hybridization; (3) Taqman double-tagging probe.When adding a pair of primer, add a specific fluorescent probe when widely used TaqMan probe method is meant pcr amplification in addition, this probe only with template specificity combine, its binding site is between two primers.5 of probe ' end be marked with the fluorescence report group (Reporter, R), as FAM, VIC etc., 3 ' end be marked with the fluorescent quenching group (Quencher, Q).When probe is complete, 5 ' end reporter group through the light source for instrument excited fluorescent just in time by in-plant 3 ' end fluorophor cancellation, instrument detecting less than 5 ' end reporter group institute excited fluorescent signal (emission wavelength of 5 ' end fluorophor just in time is the absorbing wavelength of 3 ' end fluorophor in other words, thus energy be absorbed be delivered to 3 ' end fluorophor and send other fluorescence).Carrying out along with PCR, the Taq enzyme runs in the chain extension process and template bonded probe, (this activity is a double-stranded specific to its 5 '-3 ' 5 prime excision enzyme activity, the free single-stranded probe is unaffected) will cut probe, discharging 5 ' end reporter group is free in the reaction system, away from 3 ' and the shielding of end fluorescent quenching group, 5 ' end reporter group institute's fluorescent signal emitted that is stimulated just can be detected by probe.That is to say DNA chain of every amplification, just have a fluorescence molecule to form, realized that the accumulation of fluorescent signal and PCR product form fully synchronously.From instrument detecting go out the minimum cycle number that fluorescent value goes out the peak (cycle threshold, Ct) with detect viral nucleic acid amount logarithmic value and be linear negative correlation.Just can calculate primary template amount according to the Ct value in the quantitative fluorescent PCR reaction.
(3) summary of the invention
The present invention is exactly according to above-mentioned principle, and design is fit to Auele Specific Primer and the specific probe of mumps virus, and goal of the invention is to provide gene quick detection kit and the detection method of a kind of mumps virus.
For reaching goal of the invention the technical solution used in the present invention be:
A kind of parotiditis virus fluorencent amplification detection kit, comprise mumps virus hemagglutinin gene standard substance, amplified fluorescence detection reagent and archaeal dna polymerase and reversed transcriptive enzyme, described amplified fluorescence detection reagent mainly comprises single stage method RT-PCR damping fluid, specificity amplification primer and specific probe, deoxidation nucleoside triphosphate mixture, described mumps virus hemagglutinin gene standard substance partial sequence is: 5 '-CTCAAGGACTGTTTFGCCTCTTACACCACAACCACCTGCTTTCAAGATACCGGTGA TGCTAGTG-3 ', described specificity amplification primer is: upstream primer sequence 5 '-CTCAAGGACTRTYTGCYTCSTA-3 ', downstream primer sequence 5 '-CTCTRGCATCACCGGTATCTTGAA-3 ', described specific probe sequence is: 5 "-FAM-ACCACAACCACCTGC-NFQ-MGB-3 '; wherein FAM is the report fluorophor; NFQ is non-fluorescent quenching group; itself do not produce fluorescence; can reduce the intensity of PCR reaction fluorescence background signal; MGB is a modification group, the probe annealing temperature can be improved about 10 ℃.
Described amplified fluorescence detection reagent main component is as follows:
Single stage method RT-PCR damping fluid final concentration is 1 *
Specific amplification upstream primer 0.6~1.0 μ M
Specific amplification downstream primer 0.6~1.0 μ M
Specific probe 0.2~0.5 μ M
Deoxidation nucleoside triphosphate mixture 400~800 μ M
Surplus is a DEPC water.
Above concentration is the final concentration of each material in reaction system.Deoxidation nucleoside triphosphate mixture is the mixing of dATP, dTTP, dCTP, dGTP.Described DEPC water refers to that diethypyrocarbonate (diethylpyrocarbonate) handled and through the MiliQ of high temperature, autoclave sterilization level pure water.
Described single stage method RT-PCR damping fluid final concentration is 1 *, represent that promptly each component final concentration in reaction solution is identical with each concentration of component among 1 * RT-PCR buffer in the damping fluid, each component final concentration is as follows: KCl50mM, Tris-HCl 10mM, TritonX-100 0.1%, MgCl 21.5mM.Selecting volume among the present invention for use is 5 * RT-PCR buffer of reaction solution cumulative volume 20%.
Also being added with final concentration in the described amplified fluorescence detection reagent is the RNA enzyme inhibitors RNasin of 0.8 unit of activity/μ L.The RNasin nucleic acid inhibitor is by the Promega research and development, and the RNA enzyme with wide spectrum suppresses vigor, is used to remove the RNA enzyme and pollutes.The RNasin nucleic acid inhibitor is the albumen of 1 50kD size, and it and RNA enzyme are pressed combination in 1: 1 with non covalent bond, and suppress the RNA enzyme activity, and binding constant is 10~14.The unit of activity of RNasin nucleic acid inhibitor is defined as and suppresses 5ngRNase A hydrolysis 2`, the amount of the inhibitor that 50% vigor of the single phosphoric acid cyclisation of 3`-cytidine is used.
Also be added with the DTT of final concentration 5mM in the described amplified fluorescence detection reagent.
Described deoxidation nucleoside triphosphate mixture is dATP, dTTP, dCTP, dGTP amount of substance 1: 1: 1: 1 mixture.
Described archaeal dna polymerase consumption is 0.5~5 enzyme activity unit/reaction, is selected from one of following: 1. Ampli TaqR archaeal dna polymerase; 2. rTth archaeal dna polymerase; 3. rTth archaeal dna polymerase XL.
Described reversed transcriptive enzyme consumption is 6~300 enzyme activity unit/reactions, is selected from one of following: 1. M-MuLV reversed transcriptive enzyme; 2. AMV reversed transcriptive enzyme.
Concrete, described amplified fluorescence detection reagent is composed as follows:
Single stage method RT-PCR buffer final concentration is 1 *
DTT 5mM
The RNA enzyme suppresses RNasin 0.8 unit of activity/μ L
Specific amplification upstream primer 0.88 μ M
Specific amplification downstream primer 0.88 μ M
Specific probe 0.28 μ M
Deoxidation nucleoside triphosphate mixture is:
DATP, dTTP, each 200 μ M of dCTP, dGTP
Surplus is a DEPC water.
A kind of parotiditis virus fluorencent amplification detection method, described detection method is contrast with mumps virus hemagglutinin gene standard substance, and the gargarism that adopts patient to be measured is an analyzing samples, and described method steps is as follows:
(1) gets gargarism and extract viral RNA;
(2) fluorescent PCR augmentation detection: get amplified fluorescence detection reagent and reaction required archaeal dna polymerase and reversed transcriptive enzyme and be made into reaction solution, the RNA that adds standard substance and analyzing samples carries out amplified reaction respectively, and reaction tubes places the quantitative fluorescence PCR instrument to carry out fluoroscopic examination;
(3) interpretation of result: select fluoroscopic examination model F AM fluorescence, baseline adjustment is got 3~15 round-robin fluorescent signals; The threshold setting principle is with the vertex of threshold line just above normal negative control; The fluorescence growth curve surpasses threshold line, and is good logarithmic growth, is judged as the positive;
Described mumps virus hemagglutinin gene standard substance partial sequence is: 5 '-CTCAAGGACTGTTTGCCTCTTACACCACAACCACCTGCTTTCAAGATACCGGTGAT GCTAGTG-3 ', described specificity amplification primer is: upstream primer sequence 5 '-CTC AAG GAC TRT YTG CYT CST A-3 ', downstream primer sequence 5 '-CTC TRG CAT CAC CGG TAT CTT GAA-3 ', described specific probe sequence is 5 '-FAM-ACCACAACCACCTGC-NFQ-MGB-3 ', wherein FAM is the report fluorophor, NFQ is non-fluorescent quenching group, and MGB is a modification group.Concrete, described method is got quantitative fluorescence augmentation detection reagent preparation reaction solution, and per 25 μ L are composed as follows for reaction system:
5×RT-PCR?buffer 5μL
DTT 5mM
RNA enzyme inhibitors RNasin 0.8 unit/μ L
Specific amplification upstream primer 0.88 μ M
Specific amplification downstream primer 0.88 μ M
Specific probe 0.28 μ M
Deoxidation nucleoside triphosphate mixture is:
DATP, dTTP, each 200 μ M of dCTP, dGTP
2.5 enzyme activity unit/the reactions of Ampli TaqR archaeal dna polymerase
50 enzyme activity unit/the reactions of AMV reversed transcriptive enzyme
Analyzing samples viral RNA 5 μ L
DEPC water complements to 25 μ L;
The PCR cycling condition is set to 45 ℃ of 30min reverse transcriptions, 94 ℃ of sex change 2min, and with 95 ℃ of 15s, 40 circulations of 60 ℃ of annealing 1min amplifications are carried out the single-point fluoroscopic examination at 60 ℃.The annealing temperature optimum range is 60~50 ℃, and the annealing time optimum range is 30sec~1min.
Beneficial effect of the present invention is mainly reflected in:
1, early diagnosis: PCR can directly detect pathogen nucleic acid, and is early stage in parotitis morbidity, just can detect and whether contain the mumps virus specific gene, for isolating early, make a definite diagnosis and treatment being provided convenience.
2, sampling is simple and convenient: the desirable latent period or the early stage parotitis patient respiratory road sample of falling ill detect.
3, compare with traditional gene amplification technology, detection method provided by the invention is time saving and energy saving, can finish detection in 2~3 hours.
4, highly sensitive, owing to adopted specific gene amplification and specific gene probe hybridization bonded double technique, the sensitivity of diagnosis is higher.
5, adopt the computer real-time monitoring technology, in the experiment process, can judge whether to contain virogene, and the judgement of experimental result is accurately convenient.
6, can realize the quantitative analysis of viral nucleic acid, utilize the known copy number, contain the mumps virus gene recombination plasmid and be standard substance production standard curve, can carry out quantitative analysis the viral level in the type specimen.
(4) description of drawings
Fig. 1 is mumps virus TaqMan-MGB fluorescence quantifying PCR method standard substance amplification curve diagrams, and from left to right: the viral copy number of amplification is followed successively by 10 7, 10 6, 10 5, 10 4, 10 3, 10 2, 10;
Fig. 2 is a mumps virus TaqMan-MGB fluorescence quantifying PCR method typical curve;
Fig. 3 is the circulation ratio of fluorescence quantitative RT-RCR to the mumps virus detection of nucleic acids, and from left to right: the viral copy number of amplification is followed successively by 10 6, 10 5, 10 4
Fig. 4 is the detection of TaqMan-MGB fluorescence quantitative RT-RCR to the mumps virus clinical samples,
A is the positive internal reference nucleic acid of mumps virus among the figure, and B is that the mumps virus positive contrasts nucleic acid outward.
(5) embodiment
The present invention is described further below in conjunction with specific embodiment, but protection scope of the present invention is not limited in this:
Embodiment 1:
TaqMan-MGB detection method step is as follows:
(1) extracts RNA
Get gargarism 200ul and extract viral RNA (1 μ g/ μ L) with the Reansy Mini Kit of German QIAGEN company.
(2) fluorescent PCR amplification
Get quantitative fluorescence augmentation detection reagent preparation reaction solution, reaction system is per 25 μ L, comprising:
5×RT-PCR?buffer 5μL
DTT 5mM
RNA enzyme inhibitors RNasin 0.8 unit/μ L
Specific amplification upstream primer 0.88 μ M
Specific amplification downstream primer 0.88 μ M
Specific probe 0.28 μ M
Deoxidation nucleoside triphosphate mixture is:
DATP, dTTP, each 200 μ M of dCTP, dGTP
2.5 enzyme activity unit/the reactions of Ampli TaqR archaeal dna polymerase
50 enzyme activity unit/the reactions of AMV reversed transcriptive enzyme
Analyzing samples viral RNA (1 μ g/ μ L) 5 μ L
DEPC water complements to 25 μ L;
The PCR cycling condition is set to 45 ℃ of 30min reverse transcriptions, 94 ℃ of sex change 2min, and with 95 ℃ of 15s, 40 circulations of 60 ℃ of annealing 1min amplifications are carried out the single-point fluoroscopic examination at 60 ℃.
By above-mentioned reaction solution prescription, the RNA that adds standard substance and analyzing samples prepares reaction solution respectively, carries out amplified reaction, and reaction tubes places quantitative real time PCR Instrument to carry out fluoroscopic examination; The standard substance amplification curve is seen Fig. 1, obtains typical curve and sees Fig. 2, selects viral copy number to be followed successively by 10 6, 10 5, 10 4The standard samples of/reaction carries out quantitative RT-PCR and detects, and each sample repeats to do five times, the results are shown in Figure 3 and table 1, and the Ct value variation coefficient of each concentration 5 secondary response is all less than 1%.Mumps virus clinical samples amplification curve is seen Fig. 4;
Table 1: fluorescence quantitative RT-RCR detects the circulation ratio result of mumps virus
(3) interpretation of result: select fluoroscopic examination model F AM fluorescence, baseline adjustment is got 3~15 round-robin fluorescent signals; The threshold setting principle is with the vertex of threshold line just above normal negative control; The fluorescence growth curve surpasses threshold line, and is good logarithmic growth, is judged as the positive;
Experiment shows that the Ct value variation coefficient of 5 reaction repeated of each standard nucleic acid concentration illustrates that all less than 1% the reproduction of this method is well better to the circulation ratio of mumps virus detection of nucleic acids by fluorescence quantitative RT-RCR.
Utilize this TaqMan-MGB fluorescence quantifying PCR method that some areas, Zhejiang Province doubtful mumps epidemic situation sample is detected for 35 parts, and compare with common RT-PCR method, the result shows, positive 27 parts of fluorescence quantitative PCR detection, regular-PCR detects positive 18 parts, and positive 7 parts of virus culture.The sample that RT-PCR and virus culture are positive, fluorescence quantitative RT-RCR detects also all positive, and coincidence rate is fine.
Sequence table .ST25
SEQUENCE?LISTING
<110〉Zhejiang Polytechnical University
<120〉a kind of parotiditis virus fluorencent amplification detection kit and detection method
<130>
<160>4
<170>PatentIn?version?3.2
<210>1
<211>63
<212>DNA
<213>Paramyxovirus
<400>1
ctcaaggact?gtttgcctct?tacaccacaa?ccacctgctt?tcaagatacc?ggtgatgcta 60
gtg 63
<210>2
<211>22
<212>DNA
<213>Unknown
<220>
<223〉artificial sequence
<400>2
ctcaaggact?rtytgcytcs?ta 22
<210>3
<211>24
<212>DNA
<213>Unknown
<220>
<223〉artificial sequence
<400>3
ctctrgcatc?accggtatct?tgaa 24
<210>4
<211>15
<212>DNA
<213>Unknown
<220>
<223〉artificial sequence
<400>4
accacaacca?cctgc 15

Claims (8)

1. parotiditis virus fluorencent amplification detection kit, comprise mumps virus hemagglutinin gene standard substance, amplified fluorescence detection reagent and archaeal dna polymerase and reversed transcriptive enzyme, described amplified fluorescence detection reagent mainly comprises single stage method RT-PCR damping fluid, specificity amplification primer and specific probe, deoxidation nucleoside triphosphate mixture, it is characterized in that: described mumps virus hemagglutinin gene standard substance partial sequence is: 5 '-CTCAAGGACTGTTTGCCTCTTACACCACAACCACCTGCTTTCAAGATACCGGTGAT GCTAGTG-3 ', described specificity amplification primer is: upstream primer sequence 5 '-CTCAAGGACTRTYTGCYTCSTA-3 ', downstream primer sequence 5 '-CTCTRGCATCACCGGTATCTTGAA-3 ', described specific probe sequence is: 5 '-FAM-ACCACAACCACCTGC-NFQ-MGB-3 ', wherein FAM is the report fluorophor, NFQ is non-fluorescent quenching group, and MGB is a modification group.
2. parotiditis virus fluorencent amplification detection kit as claimed in claim 1 is characterized in that described amplified fluorescence detection reagent main component is as follows:
Single stage method RT-PCR damping fluid final concentration is 1 *
Specific amplification upstream primer 0.6~1.0 μ M
Specific amplification downstream primer 0.6~1.0 μ M
Specific probe 0.2~0.5 μ M
Deoxidation nucleoside triphosphate mixture 400~800 μ M
Surplus is a DEPC water.
3. parotiditis virus fluorencent amplification detection kit as claimed in claim 2 is characterized in that also being added with in the described amplified fluorescence detection reagent RNA enzyme inhibitors RNasin that final concentration is 0.8 unit of activity/μ L.
4. parotiditis virus fluorencent amplification detection kit as claimed in claim 2 is characterized in that also being added with in the described amplified fluorescence detection reagent DTT of final concentration 5mM.
5. parotiditis virus fluorencent amplification detection kit as claimed in claim 1 is characterized in that described deoxidation nucleoside triphosphate mixture is dATP, dTTP, dCTP, dGTP amount of substance 1: 1: 1: 1 mixture.
6. parotiditis virus fluorencent amplification detection kit as claimed in claim 1 is characterized in that described archaeal dna polymerase consumption is 0.5~5 enzyme activity unit/reaction, is selected from one of following: 1. Ampli TaqR archaeal dna polymerase; 2. rTth archaeal dna polymerase; 3. rTth archaeal dna polymerase XL.
7. parotiditis virus fluorencent amplification detection kit as claimed in claim 1 is characterized in that described reversed transcriptive enzyme consumption is 6~300 enzyme activity unit/reactions, is selected from one of following: 1. M-MuLV reversed transcriptive enzyme; 2. AMV reversed transcriptive enzyme.
8. parotiditis virus fluorencent amplification detection kit as claimed in claim 1 is characterized in that described amplified fluorescence detection reagent is composed as follows:
Single stage method RT-PCR buffer final concentration is 1 *
DTT 5mM
The RNA enzyme suppresses RNasin 0.8 unit of activity/μ L
Specific amplification upstream primer 0.88 μ M
Specific amplification downstream primer 0.88 μ M
Specific probe 0.28 μ M
Deoxidation nucleoside triphosphate mixture is:
DATP, dTTP, each 200 μ M of dCTP, dGTP
Surplus is a DEPC water.
CN2006100518285A 2006-06-06 2006-06-06 Parotiditis virus fluorencent amplification detection reagent box and detection method Expired - Fee Related CN1948507B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2006100518285A CN1948507B (en) 2006-06-06 2006-06-06 Parotiditis virus fluorencent amplification detection reagent box and detection method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2006100518285A CN1948507B (en) 2006-06-06 2006-06-06 Parotiditis virus fluorencent amplification detection reagent box and detection method

Publications (2)

Publication Number Publication Date
CN1948507A CN1948507A (en) 2007-04-18
CN1948507B true CN1948507B (en) 2010-12-08

Family

ID=38018130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006100518285A Expired - Fee Related CN1948507B (en) 2006-06-06 2006-06-06 Parotiditis virus fluorencent amplification detection reagent box and detection method

Country Status (1)

Country Link
CN (1) CN1948507B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104593523A (en) * 2014-12-04 2015-05-06 湖北永邦医疗科技有限公司 Primer, probe and kit all used for detecting mumps virus
CN114836574B (en) * 2021-11-10 2023-06-16 江汉大学 MNP (MNP) marking site of mumps virus, primer composition, kit and application of MNP marking site

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064795A1 (en) * 2000-11-30 2002-05-30 Koji Hashimoto Nucleic acid detection method and apparatus, and vessel for detecting nucleic acid
CN1641355A (en) * 2004-12-20 2005-07-20 山东省医药生物技术研究中心 Protein chip for detecting blood and cerebro spinal fluid pathogen antibody, and its preparing method and use
CN2771864Y (en) * 2005-03-22 2006-04-12 山东省医药生物技术研究中心 Protein chip for detecting blood cerebrospinal fluid pathogenic antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064795A1 (en) * 2000-11-30 2002-05-30 Koji Hashimoto Nucleic acid detection method and apparatus, and vessel for detecting nucleic acid
CN1641355A (en) * 2004-12-20 2005-07-20 山东省医药生物技术研究中心 Protein chip for detecting blood and cerebro spinal fluid pathogen antibody, and its preparing method and use
CN2771864Y (en) * 2005-03-22 2006-04-12 山东省医药生物技术研究中心 Protein chip for detecting blood cerebrospinal fluid pathogenic antibody

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
严菊英等.RT-PCR快速检测腮腺炎病毒.中国公共卫生19 3.2003,19(3),347-349.
严菊英等.RT-PCR快速检测腮腺炎病毒.中国公共卫生19 3.2003,19(3),347-349. *
李敏红等.多重逆转录-聚合酶链反应检测麻疹 风疹 流行性腮腺炎病毒基因的研究.中国计划免疫11 1.2005,11(1),9-11.
李敏红等.多重逆转录-聚合酶链反应检测麻疹 风疹 流行性腮腺炎病毒基因的研究.中国计划免疫11 1.2005,11(1),9-11. *

Also Published As

Publication number Publication date
CN1948507A (en) 2007-04-18

Similar Documents

Publication Publication Date Title
CN106957927A (en) African swine fever fluorescence PCR detection reagent, African swine fever fluorescence PCR detection reagent kit and its application
CN108220480B (en) RPA fluorescent quantitative primer pair, probe and kit for specific detection of HPV18
CN102559868B (en) Method for qualitative and quantitative detection of multiple target nucleotide sequences with single tube
CN1904068B (en) H5N1 type poultry grippal virus fluorescent augmentation detection kit and detection method
CN113584224B (en) Primer probe combination, kit and detection method for detecting novel coronavirus based on LAMP technology
CN103045754B (en) One-step process real-time fluorescent quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction) method and kit for detecting Z/S subtype ebola viruses
CN113278718A (en) Primer pair, amplification reagent, amplification kit, detection method and application for detecting litopenaeus vannamei liver enterocytozoon
CN112280879A (en) RPA primer and kit for rapidly detecting citrus yellow shoot Asian species, detection method and application thereof
CN1904069B (en) Measles virus fluorescent augmentation detection kit and detection method
CN103509880A (en) LAMP detection kit of highly-pathogenic porcine reproductive and respiratory syndrome viruses
CN112831597A (en) Real-time fluorescent PCR amplification primer pair and probe primer for gene identification and detection of African swine fever virus and prepared kit
CN1948507B (en) Parotiditis virus fluorencent amplification detection reagent box and detection method
CN115803456A (en) Composition for determining false positive using specific artificial nucleotide sequence and method for determining false positive using same
CN100557030C (en) A kind of B type grippal virus fluorescent augmentation detection kit and detection method
CN102154487A (en) Reagent for detecting francisella tularensis and complex probe and fluorescent quantitative polymerase chain reaction (PCR) method for detecting francisella tularensis
CN111206122A (en) Novel coronavirus nucleic acid detection kit
CN101440400B (en) Fluorescent detection kit and method for Streptococcus suis 2 type nucleic acid containing 89K pathogenicity island gene
CN1904070B (en) Al type grippal virus fluorescent augmentation detection kit and detection method
CN105296668B (en) Primer, probe and kit for specifically detecting type 3 ungulate bocavirus parvovirus
CN113215325B (en) Reaction system, method and kit for detecting multiple HPV subtypes by two-dimensional PCR single tube closed tube
CN112322784B (en) Oligonucleotide group, kit and application thereof
CN114381551A (en) Real-time fluorescent RAA primer, probe and kit for detecting iridovirus of micropterus salmoides
CN103014164A (en) Duplex fluorescent quantitation RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection kit for shellfish Bonamia and Perkinsus
CN103882150A (en) Primer, probe and real-time fluorescent PCR (polymerase chain reaction) method for detecting TTSuV II (torque teno sus virus II)
CN117683910B (en) Detection primer group and probe for blood egg vortex dinoflagellate and application of detection primer group and probe

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101208

Termination date: 20120606